Theravance Biopharma to Participate in an Upcoming Investor Conference

Rhea-AI Summary

Theravance Biopharma (NASDAQ: TBPH) announced its participation in the upcoming BTIG Virtual Biotechnology Conference. The company will engage in a fireside chat on Wednesday, July 30 at 12:00 pm ET (9:00 am PT/5:00 pm IST). Senior management will also be available for one-on-one meetings with investors during the conference.

Interested parties can access the webcast or schedule meetings through their BTIG representative or by emailing uscorporateaccess@btig.com.

News Market Reaction – TBPH

+0.62%

1 alert

+0.62% News Effect

On the day this news was published, TBPH gained 0.62%, reflecting a mild positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

DUBLIN, July 23, 2025 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) will participate in a fireside chat at the BTIG Virtual Biotechnology Conference on Wednesday, July 30 at 12:00 pm ET (9:00 am PT/5:00 pm IST). Members of Theravance Biopharma senior management will also be hosting one-on-one meetings at the conference. To listen to the webcast or schedule meetings with management, please contact your BTIG representative or email uscorporateaccess@btig.com.

About Theravance Biopharma

Theravance Biopharma, Inc.'s focus is to deliver Medicines that Make a Difference^® in people's lives. In pursuit of its purpose, Theravance Biopharma leverages decades of expertise, which has led to the development of FDA-approved YUPELRI^® (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD). Ampreloxetine, its late-stage investigational once-daily norepinephrine reuptake inhibitor in development for symptomatic neurogenic orthostatic hypotension (nOH) in patients with Multiple System Atrophy (MSA), has the potential to be a first in class therapy effective in treating a constellation of cardinal symptoms in MSA patients. The Company is committed to creating/driving shareholder value.

For more information, please visit www.theravance.com.

THERAVANCE BIOPHARMA^®, THERAVANCE^® and the Cross/Star logo are registered trademarks of the Theravance Biopharma group of companies (in the U.S. and certain other countries).

YUPELRI^® is a registered trademark of Viatris Specialty LLC. Trademarks, trade names or service marks of other companies appearing on this press release are the property of their respective owners.

Contact:
investor.relations@theravance.com
650-808-4045

View original content to download multimedia:https://www.prnewswire.com/news-releases/theravance-biopharma-to-participate-in-an-upcoming-investor-conference-302511683.html

SOURCE Theravance Biopharma, Inc.

FAQ

When is Theravance Biopharma (TBPH) presenting at the BTIG Virtual Biotechnology Conference?

Theravance Biopharma will participate in a fireside chat on Wednesday, July 30 at 12:00 pm ET (9:00 am PT/5:00 pm IST).

How can investors access Theravance Biopharma's BTIG conference presentation?

Investors can access the webcast by contacting their BTIG representative or emailing uscorporateaccess@btig.com.

Will Theravance Biopharma management be available for meetings at the BTIG conference?

Yes, senior management will be hosting one-on-one meetings during the conference. Meetings can be scheduled through BTIG representatives.

What type of presentation will TBPH give at the BTIG Virtual Biotechnology Conference?

Theravance Biopharma will participate in a fireside chat format presentation at the virtual conference.